1 Min Read
Nov 1 (Reuters) - Inovio Pharmaceuticals Inc
* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.